Evidence map›Paper›PMID 37734292›Full record

ArticleThe American journal of cardiology2023

Proteomic Correlates of the Urinary Protein/Creatinine Ratio in Heart Failure With Preserved Ejection Fraction.

Sushrima Gan, Lei Zhao, Oday Salman, Zhaoqing Wang, Christina Ebert, Joe David Azzo, Marie Joe Dib, Payman Zamani, Jordana B Cohen, Karl Kammerhoff and 10 more

Open access · greenAbstract read
In one paragraph

Article in The American journal of cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 2 countries.

Sushrima GanDivision of Cardiovascular Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Cardiovascular Medicine, Hospital of The University of Pennsylvania, Philadelphia, Pennsylvania.
Lei ZhaoBristol-Myers Squibb Company, Lawrenceville, New Jersey.
Oday SalmanDivision of Cardiovascular Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Cardiovascular Medicine, Hospital of The University of Pennsylvania, Philadelphia, Pennsylvania.
Zhaoqing WangBristol-Myers Squibb Company, Lawrenceville, New Jersey.
Christina EbertBristol-Myers Squibb Company, Lawrenceville, New Jersey.
Joe David AzzoDivision of Cardiovascular Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Cardiovascular Medicine, Hospital of The University of Pennsylvania, Philadelphia, Pennsylvania.
Marie Joe DibDivision of Cardiovascular Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Cardiovascular Medicine, Hospital of The University of Pennsylvania, Philadelphia, Pennsylvania.
Payman ZamaniDivision of Cardiovascular Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Cardiovascular Medicine, Hospital of The University of Pennsylvania, Philadelphia, Pennsylvania.
Jordana B CohenRenal-Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Biostatistics, Epidemiology, and Informatics.
Karl KammerhoffBristol-Myers Squibb Company, Lawrenceville, New Jersey.
Peter SchaferBristol-Myers Squibb Company, Lawrenceville, New Jersey.
Dietmar A SeiffertBristol-Myers Squibb Company, Lawrenceville, New Jersey.
Francisco Ramirez-ValleBristol-Myers Squibb Company, Lawrenceville, New Jersey.
David A GordonBristol-Myers Squibb Company, Lawrenceville, New Jersey.
Mary Ellen CvijicBristol-Myers Squibb Company, Lawrenceville, New Jersey.
Kushan GunawardhanaBristol-Myers Squibb Company, Lawrenceville, New Jersey.
Laura LiuBristol-Myers Squibb Company, Lawrenceville, New Jersey.
Ching-Pin ChangBristol-Myers Squibb Company, Lawrenceville, New Jersey.
Thomas P CappolaDivision of Cardiovascular Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Cardiovascular Medicine, Hospital of The University of Pennsylvania, Philadelphia, Pennsylvania.
Julio A ChirinosDivision of Cardiovascular Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Cardiovascular Medicine, Hospital of The University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: julio.chirinos@uphs.upenn.edu.
Bristol-Myers Squibb (United States) · USHospital of the University of Pennsylvania · USUniversity of Pennsylvania · USInstitute for Medical Informatics and Biostatistics · CH

Funding

Subclinical Vascular Contributions to Alzheimer's Disease: The Multi-Ethnic Study of Atherosclerosis (MESA) Multisite Study of AD (Renewal)R01AG058969 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Timothy M. Hughes, YONGMEI LIU · 2018 to 2026
$33.4M
Understanding the relationship between obesity and tongue fat in humans and ratsP01HL094307 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MAISLIN, GREG · 2009 to 2020
$23.7M
Genomics of myocardial transcription factors in cardiac remodelingR01HL088577 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI CAPPOLA, THOMAS P. · 2007 to 2013
$5.3M
MTSS1 in Myocardial DiseaseR01HL141232 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI THOMAS P. CAPPOLA, Scott Michael Damrauer · 2019 to 2026
$4.7M
VASCULAR EFFECTS OF DIETARY SALT IN HUMANS WITH SALT-RESISTANT BPR01HL104106 · NHLBI · UNIVERSITY OF DELAWARE · PI EDWARDS, DAVID G, FARQUHAR, WILLIAM B · 2011 to 2021
$4.5M
Targeting Skeletal Muscle Perfusion and Oxidative Capacity in HFpEFR01HL155599 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI ZAMANI, PAYMAN · 2021 to 2025
$3.9M
Multidrug Metabolic Approach to Improve Exercise and Skeletal Muscle Oxidative Capacity in HFpEFR01HL157264 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI ZAMANI, PAYMAN · 2021 to 2025
$3.5M
Blockade of calcium channels and beta adrenergic receptors for physiologic abnormalities in heart failure with preserved ejection fraction (BLOCK HFpEF)R01HL153646 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI COHEN, JORDANA B. · 2020 to 2024
$3.2M
Efficacy of Potassium Nitrate in Heart Failure with Preserved Ejection FractionR01HL121510 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI CHIRINOS MEDINA, JULIO ALONSO · 2015 to 2019
$3.1M
Developing Oral LT3 Therapy for Heart FailureR33HL146390 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI CAPPOLA, ANNE R, CAPPOLA, THOMAS P. · 2020 to 2022
$2.2M
Efficacy of Fenofibrate for COVID-19: A phase II randomized controlled trialU01TR003734 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI CHIRINOS MEDINA, JULIO ALONSO · 2021 to 2021
$1.8M
HeartShare: Next-Generation Phenomics to Define Heart Failure Subtypes and Treatment Targets - Clinical CentersU01HL160277 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI JULIO ALONSO CHIRINOS MEDINA · 2021 to 2026
$1.7M
NCATS NIH HHS U01 TR003734NHLBI NIH HHS P01 HL094307NHLBI NIH HHS R01 HL088577NHLBI NIH HHS R01 HL104106NHLBI NIH HHS R01 HL121510NHLBI NIH HHS R01 HL141232NHLBI NIH HHS R01 HL153646NHLBI NIH HHS R01 HL155599NHLBI NIH HHS R01 HL157264NHLBI NIH HHS R03 HL146874NHLBI NIH HHS R33 HL146390NHLBI NIH HHS R56 HL136730NHLBI NIH HHS U01 HL160277NIA NIH HHS K24 AG070459NIA NIH HHS R01 AG058969
6 · The paper itself

Abstract

Proteinuria is common in heart failure with preserved ejection fraction (HFpEF), but its biologic correlates are poorly understood. We assessed the relation between 49 plasma proteins and the urinary protein/creatinine ratio (UPCR) in 365 participants in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Linear regression and network analysis were used to represent relations between protein biomarkers and UPCR. Higher UPCR was associated with older age, a greater proportion of female gender, smaller prevalence of previous myocardial infarction, and greater prevalence of diabetes, insulin use, smoking, and statin use, in addition to a lower estimated glomerular filtration rate, hematocrit, and diastolic blood pressure. Growth differentiation factor 15 (GDF-15; β = 0.15, p <0.0001), followed by N-terminal proatrial natriuretic peptide (NT-proANP; β = 0.774, p <0.0001), adiponectin (β = 0.0005, p <0.0001), fibroblast growth factor 23 (FGF-23, β = 0.177; p <0.0001), and soluble tumor necrosis factor receptors I (β = 0.002, p <0.0001) and II (β = 0.093, p <0.0001) revealed the strongest associations with UPCR. Network analysis showed that UPCR is linked to various proteins primarily through FGF-23, which, along with GDF-15, indicated node characteristics with strong connectivity, whereas UPCR did not. In a model that included FGF-23 and UPCR, the former was predictive of the risk of death or heart-failure hospital admission (standardized hazard ratio 1.83, 95% confidence interval 1.49 to 2.26, p <0.0001) and/or all-cause death (standardized hazard ratio 1.59, 95% confidence interval 1.22 to 2.07, p = 0.0005), whereas UPCR was not prognostic. Proteinuria in HFpEF exhibits distinct proteomic correlates, primarily through its association with FGF-23, a well-known prognostic marker in HFpEF. However, in contrast to FGF-23, UPCR does not hold independent prognostic value.

Indexed as

Heart FailureBiomarkersCreatinineFemaleGrowth Differentiation Factor 15HumansPrognosisProteinuriaProteomicsStroke VolumeBiomarkersCreatinineGrowth Differentiation Factor 15biomarkersheart failure with preserved ejection fractionplasma proteomicsproteinuriaproteomic correlates

Identifiers

PMID37734292
PMCPMC10874232
OpenAlexW4386861632

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.